Spero Therapeutics, Inc.

NasdaqGS:SPRO Stock Report

Market Cap: US$78.7m

Spero Therapeutics Future Growth

Future criteria checks 0/6

Spero Therapeutics's earnings are forecast to decline at 2.9% per annum while its annual revenue is expected to grow at 2.3% per year. EPS is expected to decline by 1.9% per annum.

Key information

-2.9%

Earnings growth rate

-1.9%

EPS growth rate

Biotechs earnings growth23.2%
Revenue growth rate2.3%
Future return on equityn/a
Analyst coverage

Low

Last updated04 Apr 2024

Recent future growth updates

Recent updates

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 12
Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jan 02
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

May 18
Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Apr 17
Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Apr 13
Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05
We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Oct 03

Spero Therapeutics appoints Kamal Hamed MD CMO

Sep 15

Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate

Sep 06

Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M

Aug 10

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

Jul 04
We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely

Sizing Up Spero Therapeutics

Oct 15

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why

Aug 11
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why

Are Institutions Heavily Invested In Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Shares?

Feb 23
Are Institutions Heavily Invested In Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Shares?

Earnings and Revenue Growth Forecasts

NasdaqGS:SPRO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202656-46-11-102
12/31/202548-63-62-613
12/31/202448-54N/A-83
12/31/202310423-33-33N/A
9/30/202378-22929N/A
6/30/202354-101212N/A
3/31/202354-2788N/A
12/31/202254-46-8-8N/A
9/30/20229-102-80-80N/A
6/30/202210-113-84-84N/A
3/31/202213-103-77-77N/A
12/31/202118-90-64-64N/A
9/30/202117-79-53-53N/A
6/30/202118-76-70-70N/A
3/31/202115-74-78-78N/A
12/31/20209-79-86-86N/A
9/30/202011-85-87-87N/A
6/30/202012-84-75-75N/A
3/31/202012-80-63-62N/A
12/31/201918-61-50-50N/A
9/30/201916-47-49-46N/A
6/30/201912-39-45-42N/A
3/31/201911-36-41-39N/A
12/31/20184-42-42-40N/A
9/30/20183-46-39-39N/A
6/30/20183-47-44-44N/A
3/31/20183-50-44-44N/A
12/31/20172-46-39-39N/A
9/30/20171-40N/A-36N/A
6/30/20171-35N/A-32N/A
3/31/20170-30N/A-29N/A
12/31/20160-30N/A-29N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SPRO's earnings are forecast to decline over the next 3 years (-2.9% per year).

Earnings vs Market: SPRO's earnings are forecast to decline over the next 3 years (-2.9% per year).

High Growth Earnings: SPRO's earnings are forecast to decline over the next 3 years.

Revenue vs Market: SPRO's revenue (2.3% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: SPRO's revenue (2.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SPRO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.